JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) announced today that its new oral contraceptive, ZOELY™ (NOMAC/E2 –nomegestrol acetate 2.5 mg/17ß-estradiol 1.5 mg), has received a Marketing Authorization in the European Union (EU) for the prevention of pregnancy. This clears the way to allow the product to be launched in Europe by the end of 2011.
